Is UHS a good stock to buy right now?

Based on our 6-factor quantitative model, UNIVERSAL HEALTH SERVICES INC (UHS) receives a "Hold" rating with a composite score of 50.1/100. It is ranked #1,750 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 77/100, Momentum 42/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for UHS?

UNIVERSAL HEALTH SERVICES INC (UHS) has a "Hold" rating and 3-star score. The composite score of 50.1 ranks it #1,750 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is UHS in?

UNIVERSAL HEALTH SERVICES INC operates in the Healthcare sector (Healthcare industry) with a market cap of $10.87 billion. It is classified as a large-cap stock.

Does UHS pay a dividend?

Yes, UHS pays a dividend with a current yield of 0.39%. For every $1,000 invested, you would receive approximately $3.90 in annual dividend income.

What is UHS's P/E ratio?

UHS has a trailing P/E ratio of 8.30x. The Healthcare sector average is 23.6x. This below-average P/E may indicate the stock is undervalued.

How profitable is UHS?

UHS's quality factor score is 50/100. Gross margin: 53.9%. ROE: 18.1% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is UHS valued compared to peers?

UHS's value factor score is 77/100 (higher = cheaper). Key multiples: P/E 8.3x, EV/EBITDA 6.4x. The stock appears attractively valued versus peers.

What is UHS's debt level?

UHS's debt-to-equity ratio is 65%. Sector average: 32%. Moderate leverage is normal for established companies.

UHS has a beta of 0.72, meaning it is less volatile than the market. Stability score: 75/100.

Does UHS have high short interest?

UHS's short interest factor score is 28/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

UHS Stock Analysis: Hold (Score 50.1/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
UHS	-3.78%	+2.31%	-3.08%	-17.08%	+1.43%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-3.71%	-1.29%	-3.42%	-16.72%	-28.10%	-	-	-
Alpha vs Sector	-2.43%	+1.97%	+0.73%	-12.24%	-7.78%	-	-	-

Metric	UHS	Benchmark
P/E Ratio	8.3x	-65%
EV/EBITDA	6.4x	+1%
Price / Book	1.5x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	44.9x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	28.1x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	16.2x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.7x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.9x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.4x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
UHS UNIVERSAL HEALTH SERVICES INC	50	50	77	42	8.3x	18.1%	53.9%	7.9%	15.0%	65.0x	$10.9B
PFE PFIZER INC	49	50	59	48	11.2x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	-	-	-	-	-	-	0.5%	0.5%	0.5%	0.5%	0.5%
Operating Margin %	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
EBITDA Margin %	0.1%	0.2%	0.1%	0.1%	0.1%	0.1%	0.2%	0.2%	0.2%	0.2%	0.2%
Net Margin %	0.1%	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
FCF Margin %	-	-	-	-	-	-	14.1%	7.1%	5.9%	6.6%	8.1%
ROE %	0.2%	0.2%	0.2%	0.1%	0.1%	0.2%	0.2%	-	0.1%	0.2%	0.2%
ROA %	0.1%	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
ROIC %	0.1%	13.0%	11.8%	8.4%	7.4%	10.4%	11.2%	22.9%	10.0%	11.3%	11.7%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.5%

Operating Margin %

0.1%

EBITDA Margin %

0.1%

0.2%

0.1%

0.2%

Net Margin %

0.1%

0.0%

0.1%

FCF Margin %

14.1%

7.1%

5.9%

6.6%

8.1%

ROE %

0.2%

0.1%

0.2%

0.1%

0.2%

ROA %

0.1%

0.0%

0.1%

ROIC %

0.1%

13.0%

11.8%

8.4%

7.4%

10.4%

11.2%

22.9%

10.0%

11.3%

11.7%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$16.8B	$17.4B	$15.8B	$14.3B	$13.4B	$12.6B	$11.6B	$11.4B	$10.8B	$10.4B	$9.8B	$9.0B
	—	—	—	—	—	—	$5.9B	$5.8B	$5.5B	$5.4B	$5.2B	$4.8B
Gross Margin	---	---	---	---	---	---	51.4%	50.9%	51.2%	52.1%	53.0%	53.4%
	—	$619M	$585M	$568M	$582M	$533M	$510M	$490M	$453M	$448M	$417M	$399M
Total Operating Expenses	—	$15.4B	$14.1B	$13.1B	$12.4B	$11.3B	—	—	—	—	—	—
	$1.9B	$2.0B	$1.7B	$1.2B	$1.0B	$1.4B	$1.4B	$1.2B	$1.2B	$1.3B	$1.3B	$1.3B
EBIT	$1.9B	$2.0B	$1.7B	$1.2B	$1.0B	$1.4B	$1.4B	$1.2B	$1.2B	$1.3B	$1.3B	$1.3B
EBITDA	$2.5B	$2.6B	$2.3B	$1.7B	$1.6B	$1.9B	$1.9B	$1.7B	$1.6B	$1.7B	$1.7B	$1.7B
Operating Margin	11.0%	11.5%	10.6%	8.2%	7.5%	10.8%	11.8%	10.7%	10.9%	12.3%	13.1%	13.9%
EBITDA Margin	14.6%	15.0%	14.3%	12.2%	11.8%	15.0%	16.2%	15.1%	15.2%	16.6%	17.4%	18.3%
	—	$156M	$186M	$207M	$127M	$84M	$106M	$163M	$155M	$145M	$125M	$113M
	—	$2.0B	$1.5B	$940M	$866M	$1.3B	—	—	—	—	—	—
Income Tax Expense	—	$461M	$335M	$221M	$209M	$306M	$299M	$239M	$237M	$364M	$409M	$395M
	$1.3B	$1.5B	$1.2B	$719M	$657M	$988M	$953M	$828M	$798M	$771M	$747M	$751M
Net Margin	7.9%	8.7%	7.3%	5.0%	4.9%	7.8%	8.2%	7.3%	7.4%	7.4%	7.6%	8.3%
	$23.42	$23.42	$17.16	$10.35	$9.23	$11.99	$11.06	$9.16	$8.35	$7.86	$7.22	$6.89
Diluted EPS	$23.42	$23.10	$16.82	$10.23	$9.14	$11.82	$11.06	$9.16	$8.35	$7.86	$7.22	$6.89
Weighted Avg Basic	—	64M	67M	69M	73M	83M	—	—	—	—	—	—
Weighted Avg Diluted	—	64M	68M	70M	74M	84M	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$16.8B

$17.4B

$15.8B

$14.3B

$13.4B

$12.6B

$11.6B

$11.4B

$10.8B

$10.4B

$9.8B

$9.0B

—

$5.9B

$5.8B

$5.5B

$5.4B

$5.2B

$4.8B

Gross Margin

---

51.4%

50.9%

51.2%

52.1%

53.0%

53.4%

—

$619M

$585M

$568M

$582M

$533M

$510M

$490M

$453M

$448M

$417M

$399M

Total Operating Expenses

—

$15.4B

$14.1B

$13.1B

$12.4B

$11.3B

—

$1.9B

$2.0B

$1.7B

$1.2B

$1.0B

$1.4B

$1.2B

$1.3B

EBIT

$1.9B

$2.0B

$1.7B

$1.2B

$1.0B

$1.4B

$1.2B

$1.3B

EBITDA

$2.5B

$2.6B

$2.3B

$1.7B

$1.6B

$1.9B

$1.7B

$1.6B

$1.7B

Operating Margin

11.0%

11.5%

10.6%

8.2%

7.5%

10.8%

11.8%

10.7%

10.9%

12.3%

13.1%

13.9%

EBITDA Margin

14.6%

15.0%

14.3%

12.2%

11.8%

15.0%

16.2%

15.1%

15.2%

16.6%

17.4%

18.3%

—

$156M

$186M

$207M

$127M

$84M

$106M

$163M

$155M

$145M

$125M

$113M

—

$2.0B

$1.5B

$940M

$866M

$1.3B

—

Income Tax Expense

—

$461M

$335M

$221M

$209M

$306M

$299M

$239M

$237M

$364M

$409M

$395M

$1.3B

$1.5B

$1.2B

$719M

$657M

$988M

$953M

$828M

$798M

$771M

$747M

$751M

Net Margin

7.9%

8.7%

7.3%

5.0%

4.9%

7.8%

8.2%

7.3%

7.4%

7.6%

8.3%

$23.42

$17.16

$10.35

$9.23

$11.99

$11.06

$9.16

$8.35

$7.86

$7.22

$6.89

Diluted EPS

$23.42

$23.10

$16.82

$10.23

$9.14

$11.82

$11.06

$9.16

$8.35

$7.86

$7.22

$6.89

Weighted Avg Basic

—

64M

67M

69M

73M

83M

—

Weighted Avg Diluted

—

64M

68M

70M

74M

84M

—

UNIVERSAL HEALTH SERVICES INC (UHS) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does UNIVERSAL HEALTH SERVICES INC Do?

Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities. The company operates through Acute Care Hospital Services and Behavioral Health Care Services segments. Its hospitals offer general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic and coronary care, pediatric services, pharmacy services, and/or behavioral health services. As of February 24, 2022, it owned and/or operated 363 inpatient facilities, and 40 outpatient and other facilities located in 39 states; Washington, D.C.; the United Kingdom; and Puerto Rico. The company also provides commercial health insurance services; and various management services, which include central purchasing, information, finance and control systems, facilities planning, physician recruitment, administrative personnel management, marketing, and public relations services. Universal Health Services, Inc. founded in 1978 and is headquartered in King of Prussia, Pennsylvania. UNIVERSAL HEALTH SERVICES INC (UHS) is classified as a large-cap stock in the Healthcare sector. The company is led by CEO Marc D. Miller and employs approximately 93,800 people, headquartered in King of Prussia, Pennsylvania. With a market capitalization of $10.9B, UHS is one of the prominent companies in the Healthcare sector.

UNIVERSAL HEALTH SERVICES INC (UHS) Stock Rating — Hold (April 2026)

As of April 2026, UNIVERSAL HEALTH SERVICES INC receives a Hold rating with a composite score of 50.1/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.UHS ranks #1,750 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, UNIVERSAL HEALTH SERVICES INC ranks #177 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

UHS Stock Price and 52-Week Range

UNIVERSAL HEALTH SERVICES INC (UHS) currently trades at $180.78. The stock lost $7.10 (3.8%) in the most recent trading session. The 52-week high for UHS is $246.32, which means the stock is currently trading -26.6% from its annual peak. The 52-week low is $152.33, putting the stock 18.7% above its annual trough. Recent trading volume was 464K shares, suggesting relatively thin trading activity.

Is UHS Overvalued or Undervalued? — Valuation Analysis

UNIVERSAL HEALTH SERVICES INC (UHS) carries a value factor score of 77/100 in the Blank Capital model, suggesting the stock trades at a meaningful discount to its fundamental earning power. The trailing price-to-earnings ratio is 8.30x, compared to the Healthcare sector average of 23.63x — a discount of 65%. The price-to-book ratio stands at 1.50x, versus the sector average of 2.75x. The price-to-sales ratio is 0.66x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, UHS trades at 6.40x EV/EBITDA, versus 6.34x for the sector.

Based on these multiples, UNIVERSAL HEALTH SERVICES INC appears attractively valued relative to both its sector peers and the broader market. Value-oriented investors may find the current entry point compelling, particularly if the company's fundamental quality metrics also score well.

UNIVERSAL HEALTH SERVICES INC Profitability — ROE, Margins, and Quality Score

UNIVERSAL HEALTH SERVICES INC (UHS) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 18.1%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 8.6% versus the sector average of -33.1%.

On a margin basis, UNIVERSAL HEALTH SERVICES INC reports gross margins of 53.9%, compared to 71.5% for the sector. The operating margin is 11.0% (sector: -66.1%). Net profit margin stands at 7.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 15.0% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

UHS Debt, Balance Sheet, and Financial Health

UNIVERSAL HEALTH SERVICES INC has a debt-to-equity ratio of 65.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.05x, suggesting adequate working capital coverage. Total debt on the balance sheet is $4.75B. Cash and equivalents stand at $113M.

UHS has a beta of 0.72, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for UNIVERSAL HEALTH SERVICES INC is 75/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

UNIVERSAL HEALTH SERVICES INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, UNIVERSAL HEALTH SERVICES INC reported revenue of $16.84B and earnings per share (EPS) of $23.42. Net income for the quarter was $1.33B. Operating income came in at $1.86B.

In FY 2025, UNIVERSAL HEALTH SERVICES INC reported revenue of $17.36B and earnings per share (EPS) of $23.42. Net income for the quarter was $1.51B. Revenue grew 9.7% year-over-year compared to FY 2024. Operating income came in at $1.99B.

In Q3 2025, UNIVERSAL HEALTH SERVICES INC reported revenue of $4.50B and earnings per share (EPS) of $5.92. Net income for the quarter was $379M. Revenue grew 13.4% year-over-year compared to Q3 2024. Operating income came in at $522M.

In Q2 2025, UNIVERSAL HEALTH SERVICES INC reported revenue of $4.28B and earnings per share (EPS) of $5.49. Net income for the quarter was $363M. Revenue grew 9.6% year-over-year compared to Q2 2024. Operating income came in at $500M.

Over the past 8 quarters, UNIVERSAL HEALTH SERVICES INC has demonstrated a growth trajectory, with revenue expanding from $3.91B to $16.84B. Investors analyzing UHS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

UHS Dividend Yield and Income Analysis

UNIVERSAL HEALTH SERVICES INC (UHS) currently pays a dividend yield of 0.4%. At this yield, a $10,000 investment in UHS stock would generate approximately $$39.00 in annual dividend income. The net margin of 7.9% provides reasonable coverage for the dividend, though investors should monitor payout sustainability.

UHS Momentum and Technical Analysis Profile

UNIVERSAL HEALTH SERVICES INC (UHS) has a momentum factor score of 42/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 27/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 28/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

UHS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, UNIVERSAL HEALTH SERVICES INC (UHS) ranks #177 out of 838 stocks based on the Blank Capital composite score. This places UHS in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing UHS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full UHS vs S&P 500 (SPY) comparison to assess how UNIVERSAL HEALTH SERVICES INC stacks up against the broader market across all factor dimensions.

UHS Next Earnings Date

No upcoming earnings date has been announced for UNIVERSAL HEALTH SERVICES INC (UHS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy UHS? — Investment Thesis Summary

UNIVERSAL HEALTH SERVICES INC presents a balanced picture with arguments on both sides. The value score of 77/100 suggests attractive pricing relative to fundamentals. Low volatility (stability score 75/100) reduces downside risk.

In summary, UNIVERSAL HEALTH SERVICES INC (UHS) earns a Hold rating with a composite score of 50.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on UHS stock.

Related Resources for UHS Investors

Explore more research and tools: UHS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare UHS head-to-head with peers: UHS vs AZN, UHS vs SLGL, UHS vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Welltower Inc. stock faces renewed interest amid senior housing demand surge and rate cut expectatio

Universal Health Services Inc. Cl B stock underperforms Friday when compared to competitors

Universal Health Services Inc. Cl B stock underperforms Tuesday when compared to competitors

Universal Health Services Inc. Cl B stock underperforms Monday when compared to competitors

Qumra backs Talkspace (TALK) sale to Universal Health Services with 5% stake

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

UNIVERSAL HEALTH SERVICES INC (UHS) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does UNIVERSAL HEALTH SERVICES INC Do?

UNIVERSAL HEALTH SERVICES INC (UHS) Stock Rating — Hold (April 2026)

UHS Stock Price and 52-Week Range

Is UHS Overvalued or Undervalued? — Valuation Analysis

UNIVERSAL HEALTH SERVICES INC Profitability — ROE, Margins, and Quality Score

UHS Debt, Balance Sheet, and Financial Health

UNIVERSAL HEALTH SERVICES INC Revenue and Earnings History — Quarterly Trend

UHS Dividend Yield and Income Analysis

UHS Momentum and Technical Analysis Profile

UHS vs Competitors — Healthcare Sector Ranking and Peer Comparison

UHS Next Earnings Date

Should You Buy UHS? — Investment Thesis Summary

Related Resources for UHS Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Welltower Inc. stock faces renewed interest amid senior housing demand surge and rate cut expectatio

Universal Health Services Inc. Cl B stock underperforms Friday when compared to competitors

Universal Health Services Inc. Cl B stock underperforms Tuesday when compared to competitors

Universal Health Services Inc. Cl B stock underperforms Monday when compared to competitors

Qumra backs Talkspace (TALK) sale to Universal Health Services with 5% stake